Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJM197304262881701DOI Listing

Publication Analysis

Top Keywords

survival patients
4
patients undergoing
4
undergoing chronic
4
chronic hemodialysis
4
hemodialysis renal
4
renal transplantation
4
survival
1
undergoing
1
chronic
1
hemodialysis
1

Similar Publications

Background: Human immunodeficiency virus continues to be a major global public health issue. Body mass index is a general indicator of nutritional status and has emerged as a powerful predictor of morbidity and mortality among adult PLHIV initiating antiretroviral therapy in resource-limited settings. However, there is a dearth of information regarding longitudinal changes in body mass index and its predictors among adult PLHIV in Ethiopia, particularly in the study area.

View Article and Find Full Text PDF

Background: The homologous recombination deficiency (HRD) test is an important tool for identifying patients with epithelial ovarian cancer (EOC) benefit from the treatment with poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi). Using whole exome sequencing (WES)-based platform can provide information of gene mutations and HRD score; however, the clinical value of WES-based HRD test was less validated in EOC.

Methods: We enrolled 40 patients with EOC in the training cohort and 23 in the validation cohort.

View Article and Find Full Text PDF

Background: Long-term care of patients with schizophrenia, which creates a burden of care, leads to disruption in interactions, social and personal relationships, changes in lifestyle, and shifts in the roles of family members. This study aimed to explore the lived experiences of family caregivers who are caring for a family member with schizophrenia within the Baloch ethnicity.

Methods: This is a qualitative study, using a descriptive phenomenological approach.

View Article and Find Full Text PDF

Background: PARP inhibitors (PARPis) have shown promising effectiveness for ovarian cancer. This network meta-analysis (PROSPERO registration number CRD42024503390) comprehensively evaluated the effectiveness and safety of PARPis in platinum-sensitive recurrent ovarian cancer (PSROC).

Methods: Articles published before January 6, 2024 were obtained from electronic databases.

View Article and Find Full Text PDF

Background: HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy for the management of dyslipidemia by enhancing the clearance of low-density lipoprotein cholesterol receptors, however recent evidence also shows links between PCSK9 and cancer cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!